A new book investigates the history of unsafe and deceptive practices by some generic drug manufacturers, and explains why U.S. regulators struggle to keep up with a global industry.
Drugmaker Mylan is launching a generic version of its own EpiPen. The lower price could quiet criticism about the high cost of the brand-name anti-allergy drug. There's also a business twist.
In testimony prepared for a congressional hearing, Mylan CEO Heather Bresch says the company makes about $50 in profit on each EpiPen. Analysts say it's still a hefty margin.